[서울경제TV=배요한기자] Seoul Pharmaceutical (018680)The US research team is rising on the news of the successful phase 2 clinical trial of famotidine, a treatment for COVID-19.
As of 1:44 pm on the 17th, Seoul Pharmaceutical is trading at 6,880 won, up 6.01% from the previous day.
According to a media on the same day, a joint research team, including Northwell Health and Cold Spring Harbor Laboratory (CSHL) Feinstein Medical Research Institute, said, “High-dose famotidine in phase 2 remote clinical trials for mild and moderate COVID-19 patients. They reported that they confirmed that they significantly reduced the incidence of symptoms in these patients.
The results of this study were published on the 10th of February in the international scientific journal ‘GUT’ in the field of the gastrointestinal tract.
In the case of the Phase 2 clinical trial, it was confirmed that the inflammation in the body resolved more quickly according to the blood test results of patients taking famotidine. In addition, it is said that the symptom improvement rate and rate of improvement were further improved in 14 out of 16 symptoms evaluated, including improvement of breathing and chest pain, cough, and abdominal pain.
Meanwhile, Seoul Pharmaceutical is selling Seoul Famotidine Tablet. /[email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >